• June 3-6, 2024
  • San Diego Convention Center, California

 

johnson and johnson
 

Our passion is to find and unleash the best innovations that could transform health outcomes for patients, wherever they originate.  Located in innovation hubs around the world, we work hand-in-hand with innovators, helping accelerate their ideas with industry-leading incubation and investment support, and deep scientific and commercial expertise from the Johnson & Johnson family of companies. 

Our portfolio is a result of our innovation-based strategy and deep scientific expertise, world-class capabilities and a source-agnostic, win-win approach to external innovation, which includes a significant investment in both Business Development and Research & Development. We remain highly active in sourcing external innovation, seeking opportunities that will best complement our existing in-market portfolio and pipeline to enable us to help elevate the standard of care for patients. 

Our goal is to identify collaborative opportunities and form active partnerships where we can bring the full strength of Johnson & Johnson to bear to create transformative value for our partners and the world. Our areas of interest include:  

  • Oncology – Including Myeloid Leukemia, B-cell Lymphoma, Multiple Myeloma, Bladder Cancer, Lung Cancer, Prostate Cancer and Immuno-Oncology.
     
  • Immunology – Including Crohn’s Disease, Ulcerative Colitis, Celiac, Inflammatory Bowel Disease, Maternal Fetal Disease, Autoantibody driven Diseases, Psoriasis, Psoriatic Arthritis, Atopic Dermatitis, Rheumatoid Arthritis, Sjogren’s, and Systemic Lupus Erythematosus.
     
  • Neuroscience – Including Alzheimer’s, Parkinson’s, Depression, Bipolar Disorder, Schizophrenia, and Neurological autoantibody driven diseases.
     
  • Cardiopulmonary – Including Atrial Fibrillation, Stroke, Cardiomyopathy, Thrombosis, Heart Failure, Pulmonary Hypertension, and Pulmonary Fibrosis.
     
  • Specialty Ophthalmology – Including Geographic Atrophy, Inherited Retinal Disorders, Retinal Vascular Diseases, and Thyroid Eye Disease.
     
  • Discovery, Product Development, and Supply – Including small molecules, Protein Therapeutics, mRNA and SiRNA Therapeutics, Drug delivery solutions, and Supply chain technologies.
     
  • Data Sciences and Digital Health – AI and ML approaches for target and biomarker identification, molecular invention, CMC, clinical trial design and process enhancement; novel digital endpoints and diagnostics.
     
  • Interventional Oncology – Including Intratumoral delivery, Radiation/Drug combinations, and Therapeutic Energy.

 

William N. Hait
Executive Vice President, Chief External Innovation and Medical Officer

“We pride ourselves on being able to spot and nurture the right opportunities at the right times, and we know what determination it takes to get innovations from idea to reality, We’re all in for the journey.”

hait

 

Nauman Shah
Global Head, Business Development, Innovative Medicine

“We pride ourselves in being partner-of-choice and will continue to advance and translate the best scientific breakthroughs into practical treatment options with differentiated value. We stand ready to work with stakeholders across the healthcare system, and through purpose-driven collaboration to accomplish truly remarkable advances in human health.”

shah

 

Stacy Feld
Regional Head, Johnson & Johnson Innovation, West North America

“Johnson & Johnson is  thrilled to return to the BIO international Convention this year! Our mission to find, nurture and accelerate innovation delivering transformative solutions has the potential to impact patient’s lives – and we know collaboration is critical to advancing breakthrough innovations. Together, we can solve the world’s biggest health challenges. We’re proud to support innovators shaping the next frontier of health and well-being and we look forward to connecting with you in San Diego.”

stacy feld

 

Meet the Johnson & Johnson External Innovation Leads for BIO 2024 !

Oncology

Felice Shieh

Early Innovation Partnering

Hong Xin

Early Innovation Partnering

Matt Lorenzi
External Innovation

Andressa Smith
Business Development

Mike Ryczyn
Business Development

Johan Verbeeck
Business Development

Leo MacDonald
Business Development

Allison Fritts
Business Development

Melissa Connor
Business Development

Cedric Delvaux
Business Development

Immunology

Toby Richardson
Early Innovation Partnering

Katherine Williams
Early Innovation Partnering

Nicola La Monica
Early Innovation Partnering

Bidisha Dasgupta
Business Development

David Keller
Business Development

Jennifer Bell
Business Development

Neuroscience

Lesley Stolz
Early Innovation Partnering

Christine Pozniak
External Innovation

Gabe Brun
Business Development

Kim Cryns
Business Development

Cindy Warren
Business Development

Elizabeth Rex
Business Development

Eric Hall
Business Development

Whitney Michiels
External Innovation

Cardiopulmonary & Specialty Opthalmology

Joerg Laeuffer

Business Development

Mike Genus
Business Development

Lisa Norquay
Business Development

Ryan Schipke
Business Development

Discovery, Product Development, and Supply

Colin Moran
Early Innovation Partnering

Sarah Lively
External Innovation

Jay Lin
External Innovation

Devin Swanson
External Innovation

Precision Medicine and Data Sciences

Eka Kortkhonjia
Early Innovation Partnering

Kara Bortone
Business Development

Interventional Oncology

Jeff Caravella
Business Development

Yao Zhang
External Innovation